HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 12%, the company's independently developed PD-1/VEGF/CTLA-4 triple antibody is expected to achieve a major breakthrough.

CSTONE PHARMA-B (02616) rose over 12%, as of the time of writing, it rose by 12.71% to HKD 6.65, with a turnover of HKD 36.9543 million. On the news front, CSTONE PHARMA-B previously announced that the company's core asset CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) for Phase II clinical trial application for advanced solid tumors has been approved by the US Food and Drug Administration (FDA). Dr. Yang Jianxin, CEO, R&D President, and Executive Director of Cstone Pharma, stated that the company is advancing the global clinical development of CS2009 and looks forward to sharing more positive data and research progress in the near future. Guoyuan released a research report stating that CSTONE PHARMA-B's core product CS2009 (PD-1/VEGF/CTLA-4 triple antibody) has excellent clinical data, with significantly better safety compared to similar therapies, achieving an ORR of 17.6% and a DCR of 82.4% in IO-treated NSCLC patients. The report noted that CS2009 is currently undergoing a global multicenter Phase II clinical study, with sites in Australia and China, with 200 patients already enrolled. The Phase II clinical trial in the US has obtained FDA approval, and data updates are expected to be released in March, along with the progress of BD collaboration.